Sinopharm Hyundai announced that the company's holding subsidiary Sinopharm Zhijun's previous marketing license transfer cooperation with Shanghai Boyue for the marketing license transfer of epiperisone hydrochloride tablets has been terminated, and the full amount of the contract amount already paid has been refunded. Sinopharm Zhijun signed a transfer agreement with Shandong Jingwei on October 21, 2026, to accept the marketing license and related rights of ethiperisone hydrochloride tablets held by it. The total transfer fee was RMB 10.00 million, and the amount was paid in installments. The drug obtained the “Drug Registration Certificate” from the State Drug Administration on July 21, 2026, and is a central muscle relaxant. The transaction had no adverse impact on the company's finances and daily operations, and there is uncertainty about matters such as subsequent license changes.

Sinopharm Hyundai announced that the company's holding subsidiary Sinopharm Zhijun's previous marketing license transfer cooperation with Shanghai Boyue for the marketing license transfer of epiperisone hydrochloride tablets has been terminated, and the full amount of the contract amount already paid has been refunded. Sinopharm Zhijun signed a transfer agreement with Shandong Jingwei on October 21, 2026, to accept the marketing license and related rights of ethiperisone hydrochloride tablets held by it. The total transfer fee was RMB 10.00 million, and the amount was paid in installments. The drug obtained the “Drug Registration Certificate” from the State Drug Administration on July 21, 2026, and is a central muscle relaxant. The transaction had no adverse impact on the company's finances and daily operations, and there is uncertainty about matters such as subsequent license changes.